Pfizer Inc. (NYSE:PFE) Shares Purchased by Alexander Labrunerie & CO. Inc.

Alexander Labrunerie & CO. Inc. grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 35.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,144 shares of the biopharmaceutical company's stock after purchasing an additional 16,367 shares during the period. Alexander Labrunerie & CO. Inc.'s holdings in Pfizer were worth $1,575,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Madison Investment Advisors LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $5,360,000. VSM Wealth Advisory LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $72,000. Finally, Royal London Asset Management Ltd. grew its stake in shares of Pfizer by 2.8% in the fourth quarter. Royal London Asset Management Ltd. now owns 2,461,076 shares of the biopharmaceutical company's stock worth $65,292,000 after acquiring an additional 67,788 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Down 0.1%

Pfizer stock opened at $24.59 on Friday. The firm has a market cap of $139.83 billion, a price-to-earnings ratio of 17.82, a PEG ratio of 0.90 and a beta of 0.58. The stock has a fifty day simple moving average of $24.02 and a two-hundred day simple moving average of $24.75. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 earnings per share. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.99%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 124.64%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on PFE. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Citigroup boosted their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. TD Cowen decreased their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. BMO Capital Markets decreased their target price on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, Redburn Atlantic decreased their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.